EZH2 anticorps (AA 1-370)

N° du produit ABIN7938125

Cité dans 9 publications. Cet anticorps anti-EZH2 Polyclonal Lapin (ABIN7938125) détecte spécifiquement EZH2 dans IP, ChIP, ChIP-seq et CUT&RUN. L’anticorps est réactif avec des échantillons de Humain et Souris.

Aperçu rapide pour EZH2 anticorps (AA 1-370) (ABIN7938125)

Antigène: EZH2 (Enhancer of Zeste Homolog 2 (EZH2))

Reactivité: Humain, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp EZH2 est non-conjugé

Application: Immunoprecipitation (IP), Chromatin Immunoprecipitation (ChIP), ChIP DNA-Sequencing (ChIP-seq), Cleavage Under Targets and Release Using Nuclease (CUT&RUN)

Détail du produit anti-EZH2 anticorps

Épitope: AA 1-370

Fonction: EZH2 antibody (pAb)

Purification: Unpurified

Immunogène: This EZH2 antibody was raised against a recombinant fusion protein corresponding to amino acids 1-370 of mouse EZH2.

Information d'application

Indications d'application: ChIP-Seq: 5 µL each CUT&RUN: 1 µL per 50 µL reaction This antibody has not been validated in WB, but a WB-validated antibody is available for this target: 39933. For EZH2, we also offer AbFlex EZH2 Recombinant Antibody (rAb). For details, see Catalog No. 91159.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Rabbit serum containing 30 % glycerol and 0.035 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles by aliquoting items into single-use fractions,Keep all reagents on ice when not in storage

Stock: -20 °C

Stockage commentaire: Some products may be shipped at room temperature. This will not affect their stability or performance. Avoid repeated freeze/thaw cycles by aliquoting items into single-use fractions for storage at -20°C for up to 2 years. Keep all reagents on ice when not in storage.

Date de péremption: 24 months

Références pour anticorps anti-EZH2 (ABIN7938125)

LaFave, Béguelin, Koche, Teater, Spitzer, Chramiec, Papalexi, Keller, Hricik, Konstantinoff, Micol, Durham, Knutson, Campbell, Blum, Shi, Doud, Krivtsov, Chung, Khodos, de Stanchina, Ouerfelli et al.: "Loss of BAP1 function leads to EZH2-dependent transformation. ..." dans: Nature medicine, Vol. 21, Issue 11, pp. 1344-9, (2015) (PubMed).

Knutson, Kawano, Minoshima, Warholic, Huang, Xiao, Kadowaki, Uesugi, Kuznetsov, Kumar, Wigle, Klaus, Allain, Raimondi, Waters, Smith, Porter-Scott, Chesworth, Moyer, Copeland, Richon, Uenaka, Pollock et al.: "Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. ..." dans: Molecular cancer therapeutics, Vol. 13, Issue 4, pp. 842-54, (2014) (PubMed).

Inoue, Kitaura, Togami, Nishimura, Enomoto, Uchida, Kagiyama, Kawabata, Nakahara, Izawa, Oki, Maehara, Isobe, Tsuchiya, Harada, Harada, Ochiya, Aburatani, Kimura, Thol, Heuser, Levine, Abdel-Wahab et al.: "Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations. ..." dans: The Journal of clinical investigation, Vol. 123, Issue 11, pp. 4627-40, (2014) (PubMed).

Kumar, Duester: "Retinoic acid controls body axis extension by directly repressing Fgf8 transcription." dans: Development (Cambridge, England), Vol. 141, Issue 15, pp. 2972-7, (2014) (PubMed).

Tong, He, Xie, Mochizuki, Liu, Mochizuki, Meng, Sun, Zhang, Guo, Hexner, Zhang: "Ezh2 regulates transcriptional and posttranslational expression of T-bet and promotes Th1 cell responses mediating aplastic anemia in mice." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 192, Issue 11, pp. 5012-22, (2014) (PubMed).

Bender, Tang, Lindroth, Hovestadt, Jones, Kool, Zapatka, Northcott, Sturm, Wang, Radlwimmer, Højfeldt, Truffaux, Castel, Schubert, Ryzhova, Seker-Cin, Gronych, Johann, Stark, Meyer, Milde, Schuhmann et al.: "Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. ..." dans: Cancer cell, Vol. 24, Issue 5, pp. 660-72, (2013) (PubMed).

Chng, Chang, Tan, Yang, Hong, Sng, Cheung: "A transcriptional repressor co-regulatory network governing androgen response in prostate cancers." dans: The EMBO journal, Vol. 31, Issue 12, pp. 2810-23, (2012) (PubMed).

Abdel-Wahab, Adli, LaFave, Gao, Hricik, Shih, Pandey, Patel, Chung, Koche, Perna, Zhao, Taylor, Park, Carroll, Melnick, Nimer, Jaffe, Aifantis, Bernstein, Levine: "ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression." dans: Cancer cell, Vol. 22, Issue 2, pp. 180-93, (2012) (PubMed).

Bredfeldt, Greathouse, Safe, Hung, Bedford, Walker: "Xenoestrogen-induced regulation of EZH2 and histone methylation via estrogen receptor signaling to PI3K/AKT." dans: Molecular endocrinology (Baltimore, Md.), Vol. 24, Issue 5, pp. 993-1006, (2010) (PubMed).

Détails sur EZH2

Antigène: EZH2 (Enhancer of Zeste Homolog 2 (EZH2))

Autre désignation: EZH2

Sujet: EZH2 - (Enhancer of Zeste homolog 2) is a human homolog of the Drosophila Polycomb-group protein Enhancer of Zeste protein. It contains a SET domain that catalyzes the methylation of histone H3 at lysine 27 (Histone H3 Lys27 monomethylated, dimethylated and trimethylated). Polycomb-group proteins repress gene expression by binding to chromatin and locally altering chromatin structure. EZH2, BMI-1 and Suz12 are present in the PRC2 and PRC3 protein complexes that function as mediators of epigenetic transcriptional silencing. EZH2 associates with the embryonic ectoderm development protein, the VAV1 oncoprotein, and the X-linked nuclear protein. EZH2 may play a role in the hematopoietic and central nervous systems. Deregulation of EZH2 is linked to a variety of cancers.

Poids moléculaire: 96 kDa

ID gène: 2146

NCBI Accession: NP_031997

Pathways: Retinoic Acid Receptor Signaling Pathway, Regulation of Muscle Cell Differentiation